Identity
- Security key
- 13585
- Ticker
- CNTB
- Type
- CS — Common Stock
- Exchange
- Nasdaq(XNAS)
- Venue group
- NASDAQ
- Operating MIC
- XNAS
- Market
- stocks
- Locale
- us
- Currency
- USD
- Listed
- 2025-09-03
- Round lot
- 100
- Active
- Yes
- Last seen in a load
- 2026-08-14 20:49
- Vendor updated
- 2026-08-13 06:09
- Ticker root / suffix
- CNTB
Detail
Enriched 2026-08-14 20:47
- Market cap
- $146,705,777.49
- Shares outstanding (class)
- 62,963,853
- Shares outstanding (weighted)
- 62,963,853
- SIC
- 2834 PHARMACEUTICAL PREPARATIONS
- Employees
- 64
- Location
- SAN DIEGO, CA
- Homepage
- https://www.connectbiopharm.com
- Description
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.